Skip to main content

The independent medical news service

Breast cancer

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

02-07-2020 | Oncology | News | Article

FDA approves outpatient combination HER2-positive breast cancer therapy

Read more on this here

01-07-2020 | Oncology | News | Article

Timing of diagnosis impacts interval breast cancer prognosis

Women with interval breast cancers diagnosed within 1 year of a negative mammogram screening result have poorer disease-specific survival than those with screen-detected cancers, US study findings indicate.

24-06-2020 | Oncology | News | Article

Mental distress high among breast cancer patients during COVID-19 peak

Women with breast cancer had higher than normal levels of severe anxiety, depression, distress, and insomnia at the peak of the COVID-19 outbreak in the Hubei Province in China, study findings indicate.

22-06-2020 | Oncology | News | Article

Alpelisib positive opinion adopted for advanced PIK3CA-mutated breast cancer

Find out about this EMA decision here

12-06-2020 | Oncology | News | Article

PHOEBE shows PFS boost with pyrotinib in HER2-positive breast cancer

Combining pyrotinib instead of lapatinib with capecitabine is associated with significantly improved progression-free survival in patients who have received prior treatment for HER2-positive metastatic breast cancer, show phase 3 trial data.

11-06-2020 | Oncology | News | Article

No survival gain with early local therapy for de novo stage IV breast cancer

Individuals who present with metastatic breast cancer do not experience improvement in overall survival or other outcomes with early locoregional therapy for an intact primary tumor, according to ECOG-ACRIN 2108 trial findings.

08-06-2020 | Oncology | News | Article

Olaparib breast cancer activity not confined to patients with germline BRCA1/2 mutations

Findings from the proof-of-principle Olaparib Expanded study indicate that patients with stage IV breast cancer and germline PALB2 or somatic BRCA1/2 mutations may benefit from olaparib treatment.

04-06-2020 | Oncology | News | Article

Switching taxane–trastuzumab to T-DM1 shows no benefit in KAITLIN trial

Adjuvant treatment with trastuzumab emtansine does not improve outcome or reduce toxicity relative to that with a taxane plus trastuzumab in patients with HER2-positive early breast cancer, results of the phase 3 KAITLIN study show.

03-06-2020 | Oncology | News | Article

Anthracyclines of no benefit in stage II/III HER2-positive breast cancer

Long-term follow-up of the TRAIN-2 study shows that patients with stage II or III HER2-positive breast cancer who receive neoadjuvant chemotherapy and dual HER2-blockade derive no survival benefit from the addition of anthracyclines.

02-06-2020 | Oncology | News | Article

BYLieve suggests alpelisib–fulvestrant benefit after progression on CDK inhibitors

The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.

30-05-2020 | Oncology | News | Article

HER2CLIMB shows intracranial efficacy of tucatinib in metastatic HER2-positive breast cancer

Tucatinib, a selective HER2 kinase inhibitor, added to trastuzumab and capecitabine has demonstrated a survival benefit in patients with HER2-positive breast cancer and brain metastases in the HER2CLIMB trial, as presented at the virtual 2020 ASCO Annual Meeting.

26-05-2020 | Oncology | News | Article

Long-term results of delayed intraoperative radiotherapy for breast cancer reported

A phase 3 trial has failed to demonstrate the noninferiority of delayed targeted intraoperative radiotherapy to whole-breast external beam radiotherapy in terms of local control at 5 years in patients with early-stage breast cancer, but other long-term outcomes were comparable.

21-05-2020 | Oncology | News | Article

monarcHER points to chemotherapy-free care for HR-, HER2-positive advanced breast cancer

Women with hormone receptor-positive, HER2-positive locally advanced, metastatic, or recurrent breast cancer might benefit from a third- or later-line regimen of the CDK4/6 inhibitor abemaciclib in combination with trastuzumab and fulvestrant, findings from the phase 2 monarcHER trial suggests.

20-05-2020 | Oncology | News | Article

HR-positive, HER2-positive breast cancer size could guide use of chemotherapy

Chemotherapy may only offer additional overall survival benefit over endocrine therapy alone for women with hormone receptor-positive, HER2-positive breast cancer size of 8–10 mm and not those with smaller tumors, report US researchers in a letter to JAMA Network Open

19-05-2020 | Oncology | News | Article

TAILORx sheds light on cognitive decline in early-stage breast cancer

An analysis of the TAILORx trial has revealed early, but not sustained, cognitive decline among breast cancer patients treated with adjuvant chemoendocrine therapy relative to endocrine therapy alone.

13-05-2020 | Oncology | News | Article

FAST-Forward data support 1-week adjuvant breast radiotherapy schedule

A phase 3 trial has demonstrated the noninferiority of two five-fraction adjuvant radiotherapy schedules delivered over a week to the standard 15-fraction schedule given over 3 weeks for early-stage breast cancer with regard to local control.

07-05-2020 | Oncology | News

Metastatic TNBC treatment receives FDA nod

Read more on sacituzumab govitecan’s approval here

06-05-2020 | Oncology | News | Article

Support for adding capecitabine to standard adjuvant TNBC chemotherapy

Women with triple-negative breast cancer have significantly better outcomes with capecitabine-containing adjuvant chemotherapy than a standard regimen, suggests a phase 3 Chinese trial.

01-05-2020 | Oncology | News | Article

Larotrectinib response best with NTRK fusion mutations

Solid tumor patients with NTRK fusion mutations experience “robust and durable responses” to treatment with larotrectinib, but those with other types of NTRK alterations derive “limited benefit” from the selective TRK inhibitor, investigators say.

Image Credits